Question special
Lead Moderator

The LAIV experience has been instructive from multiple perspectives (e.g. virology, immunology, epidemiology, policy, etc.). What lessons can we take away from LAIV for the development and implementation of live attenuated vaccines for other respiratory pathogens in the future?